Why Pay Premiums in Biotech M&A

3 major MASH acquisitions in under a year. Roche, GSK, now Novo. Combined value over $9B. The market's sending a clear signal: MASH has moved from speculative to strategic necessity. Here's the competitive dynamic playing out: Novo owns GLP-1s. Wegovy and Ozempic generate tens of billions annually. MASH frequently stems from obesity. Acquiring Akero Therapeutics efruxifermin gives them both ends of the treatment spectrum. They can address the obesity AND the downstream liver damage. No one else has that combination. Roche paid $3.5B for 89Bio's pegozafermin last month. Similar mechanism to efruxifermin (FGF21 analog). They're betting on a parallel path to the same market. The clinical data showed comparable efficacy, so Roche bought its way into the race rather than starting 5 years behind. GSK grabbed Boston Pharmaceuticals experimental MASH drug for $1.2B upfront earlier this year. Different mechanism (THR-β agonist), potentially complementary to FGF21 approaches. They're hedging on mechanism diversity. What this tells us: The big pharma companies with deep metabolic disease franchises have decided MASH can't be ignored anymore. The patient population is massive (6-8% globally), growing with obesity rates, and there's almost no effective treatment currently available. The companies that waited are now paying premiums to catch up. Novo Nordisk's 16% premium looks reasonable until you factor in the 42% run-up from acquisition speculation. Roche paid a 127% premium for 89bio. GSK went straight to a $1.2B upfront payment before the asset even hit meaningful clinical milestones. Early movers got better deals. Late movers are paying for speed. The next 3-5 years will determine which mechanisms actually work in MASH. Multiple programs have failed spectacularly. The ones that succeed will define a $10B+ market. The ones that fail will write off billions in acquisition costs. But here's what's interesting: None of these companies could afford NOT to play. If MASH programs succeed and you're not in the game, you've ceded an entire treatment category to competitors. The cost of missing this market is higher than the cost of buying in. We're watching portfolio strategy play out in real time. Companies aren't just buying drugs. They're buying optionality on a market that might explode or might collapse, and they've decided the risk of missing it is worse than the cost of entry. What do you think drives the better ROI here - mechanism diversity or doubling down on proven approaches like FGF21? #Biotech #Pharma #Strategy #MASH #M&A

Big pharma dropped $6.6B on in-vivo CAR-T startups in under a year. But this only a small niche compared to the entire Biotech M&A space. For In Vivo cell engineering From March until last October: Bristol Myers Squibb → Orbital Therapeutics ($1.5B) Gilead/Kite → Interius ($350M) + Pregene ($1.64B) AbbVie → Capstan Therapeutics ($2.1B) AstraZeneca → EsoBiotec ($1B) So why Big Pharma prefers to buy instead of build own R&D programs? Three reasons small biotechs win at innovation: #1 Cost advantage Big pharma's overhead is massive. Executive layers, complex infrastructure, global operations. A fully loaded FTE at J&J costs far more than at a 50-employee biotech. Small companies run lean and hungry. #2 Laser focus Big pharma kills programs at the first sign of trouble. "Fail early" sounds smart, but most successful drugs survived near-death moments. Small biotechs can't afford to quit. They only have 1-2 programs. That desperation breeds breakthroughs. #3 Organizational alignment Ever heard of the organizational iceberg? In large companies, only 4% of problems reach senior management. In a startup, the CEO knows everything happening at the bench. No layers. No information loss. Everyone's aligned on the mission. As a curious note you can read about the critical operational number defined by Dunbar (link below). In 2024, only 23 of 55 FDA approvals came from companies with $3B+ in sales. Small biotechs are outinnovating giants. Big pharma just figured this out. Why fund 10 risky programs internally when you can let the market fund 100 and cherry-pick the winners? It's not laziness. It's strategy. What's your take?

When a Strategic Buyer looks at your company, they aren't just seeing what you are... they are calculating what you could be in their hands. This is called Synergy, and it is the primary justification for high M&A premiums. There are two main types you need to articulate in your pitch: 1. Cost Synergies (The "Hard" Numbers) These are efficiency gains, cutting redundant costs. • Examples: Closing duplicate headquarters, streamlining supply chains, or combining R&D teams. • Why it matters: These are "hard" synergies because they are high-confidence. Buyers pay for these because they can practically guarantee the savings. When Exxon merged with Mobil, they generated over $5 billion in cost synergies by eliminating overlaps. 2. Revenue Synergies (The "Soft" Numbers) This is about growth, selling more together than you could alone. • Examples: Cross-selling your software to their enterprise clients or using their global distribution network for your local product. • The Case Study: When Disney acquired Pixar, it wasn't just for the movies. It was for the ability to push Pixar characters through Disney theme parks and stores—massive value creation neither could achieve alone. The Founder’s Job Buyers often underestimate synergies to protect their ROI. Your job is to "document the opportunities". Don't just list your features; quantify how your technology reduces their costs or how your IP accelerates their roadmap. Cost synergies are realized faster, but Revenue synergies offer the highest theoretical ceiling. If you can prove the math on both, you force the buyer to raise their Maximum Allowable Purchase Price.

🔥 Avidity Biosciences, Inc.’s #Hardball #Strategy Pays Off: How a $7.4B Offer Became a $12B #Acquisition by Novartis One of the most fascinating biotech M&A negotiations of 2025 just unfolded — and Avidity Biosciences, Inc. Biosciences showed a masterclass in leverage, timing, and conviction. Regulatory filings reveal how Sarah Boyce and her team turned down multiple offers from Novartis, even cutting off access to the data room and kicking off a massive capital raise — ultimately pushing Vas Narasimhan to increase the acquisition price by more than 60%, landing at $12B. Here are the strategic highlights: 1️⃣ 💼 Know Your Worth — and Defend It Avidity firmly believed in the upside of its RNA therapeutic programs (notably del-zota & del-brax) and refused to settle. Their insistence on value forced Novartis to repeatedly revise its bid. 2️⃣ 🧪 Data Wins Deals Positive Phase I/II signals in facioscapulohumeral muscular dystrophy (FSHD) and strong Duchenne muscular dystrophy (DMD) data in September massively increased Avidity’s negotiating power. 3️⃣ 🚪 Walking Away Is a Power Move When Avidity cut Novartis’ access to the data room and advanced a $690M capital raise, they sent a clear message: we don’t need this deal to survive. That boldness was key to extracting a higher offer. 4️⃣ 📰 Rumors Move Markets Media leaks (Financial Times) spiked Avidity’s stock, strengthened its valuation floor, and forced Novartis to accelerate diligence — a real-world reminder that information flow can shape deal dynamics. 5️⃣ 🏁 Persistence Pays — for Both Sides Despite multiple rejections, Vas Narasimhan stayed personally involved, ultimately delivering $72/share and securing a strategic platform fit for Novartis’ long-term neuromuscular ambitions. 💬 My Take: This deal is a rare case study in biotech bargaining strength, fueled by clinical momentum and strong leadership discipline. For emerging biotechs, the lesson is clear: 👉 A robust standalone plan is the strongest negotiating tool you have. #Avidity #Novartis #BiotechDeals #MergersAndAcquisitions #DMD #FSHD #RNAtherapeutics #Leadership #Negotiation #LifeSciences #DrugDevelopment https://lnkd.in/gQnwnxBv

Novo Nordisk and Pfizer are locked in a takeover battle for Metsera, a sign of the times in biopharma. Aggressive outreach like this says a lot about the current environment: pipeline pressure, fierce competition for differentiated assets, and the growing willingness to pursue deals outside the usual playbook. Premiums are paid because the cost of missing out is even higher. But it’s worth looking past the headlines: These moves only pay off if the integration creates value beyond the price tag. That’s rarely straightforward. Most unsolicited deals come from necessity, not opportunity. How often do they actually deliver sustainable advantage? History is mixed at best. What happens after the dust settles, how the winning bidder integrates, how much the data delivers, and whether clinical differentiation is as real as the multiples, will reveal whether these aggressive moves are savvy strategy or simply the cost of keeping up. Plenty to debate. Where do you think this arms race is headed? https://lnkd.in/gzgdDTGC